Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Colorectal Neoplasms × anlotinib × Clear all

Phase

Phase 2 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 1 Sarcoma 1 Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Differentiated Thyroid Cancer 1 Colorectal Neoplasms 1 Carcinoma, Medullary 1 Biliary Tract Neoplasms 1 Advanced Solid Tumor 1

Interventions

Oxaliplatin 15 Fluorouracil 13 Bevacizumab 11 Leucovorin 10 Capecitabine 8 Folfox protocol 7 Irinotecan 5 IFL protocol 4 Cetuximab 4 Folic Acid 3 Aspirin 3 XELOX 2 Surgical Procedures, Operative 2 Magnetic Resonance Spectroscopy 2 Drug Therapy 2 Chemotherapy, Adjuvant 2 trifluridine tipiracil drug combination 1 trametinib 1 titanium silicide 1 sulindac sulfone 1 spartalizumab 1 sacituzumab govitecan 1 regorafenib 1 pertuzumab 1 folfirinox 1 dabrafenib 1 cobimetinib 1 cediranib 1 atezolizumab 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02332499 2019-05-21

ALTER0703

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡